Physician profile
Adrian Jaffer
NPI 1366476152
$3,293.24
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,810 · 2020: $774 · 2021: $650 · 2022: $41.07 · 2023: $17.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $403.49 | 2019-2021 | |
| Glaxosmithkline, LLC. | $384.97 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $359.20 | 2019-2023 | Tezspire |
| Amgen INC. | $256.47 | 2019-2021 | |
| Abbvie INC. | $224.54 | 2019-2022 | |
| Genentech USA, INC. | $204.20 | 2019-2020 | |
| Pfizer INC. | $186.44 | 2019-2021 | |
| Kaleo, INC. | $123.44 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.43 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $114.36 | 2019-2020 | |
| Ucb, INC. | $104.34 | 2019-2021 | |
| Shire North American Group INC | $84.81 | 2019 | |
| Medexus Pharma, INC. | $84.64 | 2019-2020 | |
| Lilly USA, LLC | $83.68 | 2019-2021 | |
| Genzyme Corporation | $80.23 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $78.12 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $74.37 | 2019-2021 | |
| Celgene Corporation | $45.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $42.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.96 | 2019 | |
| Sobi, INC | $36.17 | 2019-2020 | |
| Csl Behring | $35.98 | 2019-2020 | |
| Alk-Abello, INC | $34.55 | 2019-2020 | |
| Pacira Therapeutics, INC. | $26.32 | 2020 | |
| Depuy Synthes Sales INC. | $21.81 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.73 | 2019 | |
| Optinose US, INC. | $20.81 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Jaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.